Neuron23™ Inc. is an early-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases. The Company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases.
Our intention is simple, but our work is not. Combining cutting-edge data science and human genetics, we're creating precision medicines to fight debilitating diseases. With a diverse patient population and multiple factors driving disease, we know a personalized approach is essential. This is how we identify those most likely to respond favorably to our treatments, as well as translatable disease-relevant biomarkers to efficiently measure our impact early in clinical development.
Total Funding: N/A
Funding Stage: N/A
Business Stage: Scaling Up
Market: B2B2C, B2C, B2B
Company Size: 26 to 50
Founded: 2018
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Neuron23
Adam Knight
Founder and Chief Business Officer
Karen L.
VP, Finance & Corporate Controller
Jim Zheng
Senior Director
